Sequential versus standard triple first-line therapy forHelicobacter pylorieradication (Q26471410)

1

0 references

Adrian G McNicholl

2

0 references

Vincenzo Savarino

4

0 references

Giuseppina Oderda

5

0 references

Carlo A Fallone

6

0 references

Lori Fischbach

7

0 references

Franco Bazzoli

8

0 references

Javier P Gisbert

Cochrane Database of Systematic Reviews

9

0 references

publication date

28 June 2016

0 references

published in

0 references

cites work

Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Meta-analysis, Simpson's paradox, and the number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Two new treatment regimens for Helicobacter pylori eradication: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Meta-analysis: principles and procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

How can the current strategies for Helicobacter pylori eradication therapy be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Eradication therapy for peptic ulcer disease inHelicobacter pylori-positive people

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Evolution of Helicobacter pylori therapy from a meta-analytical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

III Spanish Consensus Conference on Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Intention-to-treat concept: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Meta-analysis: sequential therapy for Helicobacter pylori eradication in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Eradication of Helicobacter pylori: recent advances in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Pooling data for number needed to treat: no problems for apples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

High Helicobacter pylori numbers are associated with low eradication rate after triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Rating methodological quality: toward improved assessment and investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori detection and antimicrobial susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential regimens for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential versus standard triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

A new highly effective short-term therapy schedule for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Letter: the ethics of using inferior regimens in H. pylori randomised trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

A report card to grade Helicobacter pylori therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021

Ethical considerations of comparing sequential and traditional anti Helicobacter pylori therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009034.PUB2

7 January 2021